Predicted to enable phosphotyrosine residue binding activity. Predicted to act upstream of or within several processes, including hematopoietic stem cell proliferation; negative regulation of oocyte maturation; and positive regulation of immune response. Predicted to be located in cytoplasmic ribonucleoprotein granule; cytosol; and nucleoplasm. Orthologous to human SHB (SH2 domain containing adaptor protein B); PARTICIPATES IN platelet-derived growth factor signaling pathway; vascular endothelial growth factor signaling pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran; 6-propyl-2-thiouracil.
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA
[bisphenol A co-treated with Fulvestrant] results in increased methylation of SHB gene, [bisphenol F co-treated with Fulvestrant] results in increased methylation of SHB gene
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA